Ginkgo Bioworks Holdings (DNA) Retained Earnings (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Retained Earnings came in at $1.2 million in Q1 2026, down 99.98% YoY from $6.6 billion in Q1 2025, and down 35.49% on a QoQ basis from $1.9 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Retained Earnings (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Retained Earnings data on file, last reported at $1.2 million in Q1 2026.
- Quarterly Retained Earnings fell 99.98% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 99.98% YoY) and the FY2025 annual result came in at $1.9 million, up 202.49% from the prior year.
- Retained Earnings retreated to $1.2 million in Q1 2026, from $1.9 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $6.6 billion in Q1 2025 to a low of -$5.7 billion in Q3 2024.
- A 5-year average of -$134.6 million and a median of $1.2 million in 2026 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings plunged 57832.02% — and 2024, when it surged 399422.06%.
- Tracing DNA's Retained Earnings over 5 years: stood at -$4.4 billion in 2022, then jumped by 245.22% to $6.4 billion in 2023, then plunged by 100.03% to -$1.8 million in 2024, then soared by 202.49% to $1.9 million in 2025, then plunged by 35.49% to $1.2 million in 2026.
- The last three Retained Earnings figures came in at $1.2 million (Q1 2026), $1.9 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | 6.70 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.70 Bn |
| Mar 31, 2026 | 1.19 Mn |
| Dec 31, 2025 | 1.85 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | 1.65 Mn |
| Mar 31, 2025 | 6.58 Bn |
| Dec 31, 2024 | -1.81 Mn |
| Sep 30, 2024 | -5.73 Bn |
| Jun 30, 2024 | -5.67 Bn |
| Mar 31, 2024 | 6.45 Bn |
| Dec 31, 2023 | 6.39 Bn |
| Sep 30, 2023 | -5.08 Bn |
| Jun 30, 2023 | 6.28 Bn |
| Mar 31, 2023 | -1.61 Mn |
| Dec 31, 2022 | -4.40 Bn |
| Sep 30, 2022 | -4.22 Bn |
| Jun 30, 2022 | 5.20 Mn |
| Mar 31, 2022 | -2.88 Bn |
| Dec 31, 2021 | -2.30 Bn |
| Sep 30, 2021 | -697.27 Mn |